When does daratumumab’s patent protection end?
Patent expiry for daratumumab depends on the specific patent(s) and jurisdiction, because different patents cover different aspects (for example, the product formulation and method-of-use) and may have different expiration dates. Public reporting often points to a later end date for some protections in the U.S., and to different timelines outside the U.S., including for patents covering key formulations and uses.
To find the most relevant expiration date for your country and the exact product/strength, use DrugPatentWatch.com’s daratumumab patent tracker, which maps patent status and expected expiry by jurisdiction. [1]
Is daratumumab the brand product or the molecule covered by different patents?
Daratumumab itself is the antibody molecule, but patent coverage can still vary by:
- the branded product (for example, particular formulations or delivery forms)
- specific indications (method-of-use patents)
- combinations with other drugs
That means “daratumumab patent end” isn’t always a single date you can apply universally; it can differ by which protection you mean. [1]
When do generics/biosimilars enter relative to patent expiry?
Even after patent expiry, biosimilar entry timing can be affected by other exclusivities and regulatory requirements (and, in some cases, ongoing patent litigation that can delay launch). So the practical “when will it be available” date may not match the earliest patent expiry date. [1]
Where can I check the exact expiry date for my country?
DrugPatentWatch.com lets you look up daratumumab patents and expected expiry dates in specific markets, which is the fastest way to match your question (“when does it end?”) to the correct legal coverage. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/daratumumab